SCHEMBL4318870

SCHEMBL4318870

CC(C)C[C@H](N)C(=O)NO

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.56
LARS1 Q9P2J5 3/20 0.46
ANPEP P15144 7/20 0.46
RNPEP Q9H4A4 2/20 0.46
DNPEP Q9ULA0 2/20 0.46
AAK1 Q2M2I8 1/20 0.44
SLC1A3 P43003 1/20 0.43
SLC1A2 P43004 1/20 0.43
MMP8 P22894 3/20 0.41
MMP2 P08253 2/20 0.40
MMP9 P14780 1/20 0.40
MMP1 P03956 1/20 0.39
LAP3 P28838 2/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
ERAP1 Q9NZ08 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2517387 1.00 SLC7A5 (0.56) SLC7A5LARS1ANPEPRNPEPDNPEP
SCHEMBL246046 1.00 SLC7A5 (0.56) SLC7A5LARS1ANPEPRNPEPDNPEP
SCHEMBL1174387 0.81 SLC7A5 (0.56) SLC7A5LARS1ANPEPRNPEPDNPEP
SCHEMBL836565 0.81 SLC7A5 (0.56) SLC7A5LARS1ANPEPRNPEPDNPEP
SCHEMBL19559844 0.81 SLC7A5 (0.56) SLC7A5LARS1ANPEPRNPEPDNPEP
SCHEMBL4677717 0.81 SLC7A5 (0.56) SLC7A5LARS1ANPEPRNPEPDNPEP
SCHEMBL8330499 0.81 SLC7A5 (0.56) SLC7A5LARS1ANPEPRNPEPDNPEP
SCHEMBL2715188 0.81 SLC7A5 (0.56) SLC7A5LARS1ANPEPRNPEPDNPEP
SCHEMBL10296149 0.79 SLC7A5 (0.54) SLC7A5LARS1ANPEPRNPEPDNPEP
SCHEMBL13789959 0.79 SLC7A5 (0.54) SLC7A5LARS1ANPEPRNPEPDNPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4599826-A1 LEUCINE FOR USE IN THE TREATMENT OF CANCER IFOM - Istituto Fondazione di Oncologia Molecolare ETS (IT) 2025-08-13 EP disclosed
US-11446398-B2 Regulated biocircuit systems OBSIDIAN THERAPEUTICS, INC. (US) 2022-09-20 US disclosed
US-20210254056-A1 IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS CAMP4 THERAPEUTICS CORPORATION 2021-08-19 US disclosed
US-20190192691-A1 REGULATED BIOCIRCUIT SYSTEMS OBSIDIAN THERAPEUTICS, INC. 2019-06-27 US disclosed
WO-2018204764-A1 IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS CAMP4 THERAPEUTICS CORPORATION (US) 2018-11-08 WO disclosed
EP-2511844-B1 X-ray microscope XRPRO SCIENCES INC (US) 2015-08-12 EP disclosed
EP-2511844-A2 Advanced drug development and manufacturing Los Alamos National Security, LLC (US) 2012-10-17 EP disclosed
EP-2084519-A2 ADVANCED DRUG DEVELOPMENT AND MANUFACTURING Los Alamos National Security, LLC (US) 2009-08-05 EP disclosed
WO-2008127291-A2 ADVANCED DRUG DEVELOPMENT AND MANUFACTURING LOS ALAMOS NATIONAL SECURITY, LLC (US) 2008-10-23 WO disclosed
WO-2002085369-A1 INHIBITORS OF ANTHRAX LETHAL FACTOR ACTIVITY STRUCTURAL BIOINFORMATICS, INC. (US) 2002-10-31 WO disclosed
US-6436933-B1 1-HYDROXY-3-(2-METHYLPROPYL)-5,6-DIPHENYLHYDROPYRAZIN-2-ONE STRUCTURAL BIOINFORMATICS INC. 2002-08-20 US disclosed
US-4183786-A FROM GYLCINE BY CULTURING MUTANT OF NOCARDIA KYOWA HAKKO KOGYO CO., LTD. (JP) 1980-01-15 US disclosed